

May 11, 2023

To The Manager, Listing Department <b>National Stock Exchange of India Limited</b> Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: <b>BLISSGVS</b>	To The General Manager, Listing Department <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: <b>506197</b>
---	--

**Subject: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith a disclosure of Related Party Transactions in the specified format for the half year ended March 31, 2023.

Kindly take the same on your record.

Thanking you,

Yours faithfully,

For **Bliss GVS Pharma Limited**

**Deepak B. Sawant**  
**Chief Financial Officer**

Encl: as above

**Regd. Office :** 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

**Factory :** Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.  
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com



	Bliss GVS Pharma Limited	Mr. S. N. Kamath	Promoter and Relative of Director (from 12.05.21)	Refundable deposit for Leave License	-	0	48.75	48.75	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Geeta N. Kamath	Relative of Director (from 12.05.21)	Payment of Rent	-	2.03	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Mrs. Shruti Vishal Rao	Director	Remuneration	-	34.33	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Dr. Vibha Gagan Sharma	Director	Remuneration	-	36.41	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Mr. Gagan Harsh Sharma	Managing Director	Remuneration	-	93.63	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Mr. Vishal Rao	Relative of Director	Remuneration	-	34.33	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Mr. Deepak Sawant	Key management personnel of entity or parent (resigned w.e.f. 30.12.2022)	Remuneration	-	16.29	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Ms. Aditi Bhatt	Key management personnel of entity or parent	Remuneration	-	6.60	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Bliss GVS International Pte Ltd	Wholly Owned Subsidiary	Investment in Share Capital	-	-	22.58	22.58	-	-	-	Investment in equity	NA	NA	Unsecured	Investment made for business purpose
	Bliss GVS Pharma Limited	Bliss GVS International Pte Ltd	Wholly Owned Subsidiary	Interest Income/ Receivable	450	201.83	712.91	888.92	-	-	-	-	-	-	-	-

	Bliss GVS Pharma Limited	Bliss GVS International Pte Ltd	Wholly Owned Subsidiary	Loan and Advances	15000	-	8804.92	8876.69	-	-	-	Loan	4.5-6.33%	Repayable on Demand	Unsecured	Loan utilised for working capital
	Bliss GVS Pharma Limited	Bliss GVS International Pte Ltd	Wholly Owned Subsidiary	Sale of Goods	500	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Bliss GVS International Pte Ltd	Wholly Owned Subsidiary	Purchase of Goods	20	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Kremoint Pharma Pvt Ltd	Subsidiary	Labour Charges and purchases of goods/Payable	100	40.82	7.79	14.41	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Kremoint Pharma Pvt Ltd	Subsidiary	Dividend Received	13	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Kremoint Pharma Pvt Ltd	Subsidiary	Investment in Share Capital	2500	-	1,803.00	1,803.00	-	-	-	Investment in equity	NA	NA	Unsecured	Investment made for business purpose
	Bliss GVS Pharma Limited	Kremoint Pharma Pvt Ltd	Subsidiary	Interest Income/Receivable	1	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Kremoint Pharma Pvt Ltd	Subsidiary	Sale of Goods/Receivable	250	5.40	19.27	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Kremoint Pharma Pvt Ltd	Subsidiary	Loans and Advances	100	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences Limited (UK)	Wholly Owned Subsidiary	Investment In Share Capital	1	-	0.10	0.10	-	-	-	Investment in equity	NA	NA	Unsecured	Investment made for business purpose

	Bliss GVS Pharma Limited	Asterisk Lifesciences Limited (UK)	Wholly Owned Subsidiary	Loans and Advances	1000	-	18.05	20.25	-	-	-	-	-	-	-	Loan utilised for working capital
	Bliss GVS Pharma Limited	Asterisk Lifesciences Limited (UK)	Wholly Owned Subsidiary	Interest Income /Receivable	1	0.50	2.58	3.46	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences GH Limited	Step-down Subsidiary	Investment in Share Capital	10	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences GH Limited	Step-down Subsidiary	Reimbursement of Expenses received	50	3.92	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences GH Limited	Step-down Subsidiary	Sale of Goods/Receivable	15000	3,029.78	8,801.94	9,276.21	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences GH Limited	Step-down Subsidiary	Loans and Advances	1000	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Greenlife Bliss Healthcare	Step-down Subsidiary	Loans and Advances	100	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Greenlife Bliss Healthcare	Step-down Subsidiary	Sale of Goods/Receivable	100	-	7.31	12.33	7.31	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Greenlife Bliss Healthcare	Step-down Subsidiary	Purchase of Goods	10	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	EIPII Exports Pvt Ltd.	Step-down Subsidiary	Sale of Goods/Receivable	102.32	-	58.59	58.59	-	-	-	-	-	-	-	-
	Bliss GVS	Lozen Pharma	Directors are Members/Share	Purchase of Goods/Payable	750	257.81	71.99	141.29								

	Pharma Limited	Pvt Ltd.	holders													
	Bliss GVS Pharma Limited	Lozen Pharma Pvt Ltd.	Directors are Members/Share holders	Advance received against lease rights/assets	63.73	63.73	-	63.73								
	Bliss GVS Pharma Limited	Asterisk Lifesciences DRC	Step-down Subsidiary	Sale of goods	15000	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences DRC	Step-down Subsidiary	Loans and Advances	1000	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences DRC	Step-down Subsidiary	Reimbursement of Expenses	500	-	2.11	2.13	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences DRC	Step-down Subsidiary	Investment In Share Capital	10	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Plastic Ingenuities (I) Pvt Ltd	Directors are Members/Share holders	Purchase of Goods	25	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Plastic Ingenuities (I) Pvt Ltd	Directors are Members/Share holders	Reimbursement of Expenses	3	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Plastic Ingenuities (I) Pvt Ltd	Directors are Members/Share holders	Sales of Goods	5	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Bliss GVS Charitable Trust	Enterprise over which KMP exercises significant influence	Donation	60	35.00	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma	Greenlife Pharmaceuticals	Related Party of Step-down Subsidiary	Sale of Goods/Receivables	-	7,208.10	-	6,209.97								

	Limited															
	Bliss GVS Pharma Limited	Greenlife Pharmaceuticals	Related Party of Step-down Subsidiary	Business Promotion Expenses	-	239.38	-	-								
	Bliss GVS Pharma Limited	Greenlife Pharmaceuticals	Related Party of Step-down Subsidiary	Advance from Customer Outstanding	-	6.18	-	0.31								
	Bliss International Pte Ltd	Green life Bliss Healthcare Ltd	Step-down Subsidiary	Investment in Shares	-		3.47	3.47								
	Bliss International Pte Ltd	Green life Bliss Healthcare Ltd	Step-down Subsidiary	Loan Given	-		4,441.97	4,827.71								Loan utilised for working capital
	Bliss International Pte Ltd	Asterisk Lifesciences DRC	Step-down Subsidiary	Loan Given	-	78.79		78.79								Loan utilised for working capital
	Bliss International Pte Ltd	Asterisk Lifesciences DRC	Step-down Subsidiary	Investment in Shares	-	-	0.74	0.74								
	Asterisk Lifesciences Limited (UK)	Asterisk Lifesciences (GH) Limited	Step-down Subsidiary	Investment in Shares			691.58	691.58								
	Asterisk Lifesciences Limited (UK)	Asterisk Lifesciences (GH) Limited	Step-down Subsidiary	Purchases/Payables			670.89	706.63								
	Kremoin Pharma Pvt Ltd	Mr Bhadresh Keshavji Thakkar	KMP of Subsidiary	Salary		66	-	-								
	Kremoin	Mr	KMP of	Dividend Paid		3.57	-	-								

	t Pharma Pvt Ltd	Bhadresh Keshavji Thakkar	Subsidiary													
	Kremoin t Pharma Pvt Ltd	Ms. Yesha Bhadresh Thakkar	Relative of KMP of Subsidiary	Salary		29.90	-	-								
	Kremoin t Pharma Pvt Ltd	Ms. Yesha Bhadresh Thakkar	Relative of KMP of Subsidiary	Bonus		1.58	-	-								
	Kremoin t Pharma Pvt Ltd	Mrs. Hema Bhadresh Thakkar	Relative of KMP of Subsidiary	Dividend Paid		1.83										
	Kremoin t Pharma Pvt Ltd	Eipii Exports Pvt Ltd	Step down Subsidiary	Sales		149.13	-	-								
	Kremoin t Pharma Pvt Ltd	Yash Jain	Relative of KMP of Subsidiary	Salary		2.25	-	-								
	Eipii Exports Pvt Ltd	Ritu Thakkar	Relative of KMP of step down Subsidiary	Salary		31.68	-	-								
	Greenlif e Bliss HealthC are Ltd	Greenlife Pharmace uticals Ltd	Shareholder	Sale of Goods/ Receivable		2,278.58	2,278.95	2,167.15								
Total (of Note 6b)																

Note: Foreign balances are reinstated wherever applicable

**Notes:**

1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.

2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.

3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.

4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly.



5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.

6. In case of a multi-year related party transaction:

- a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
- b. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".

7. "Cost" refers to the cost of borrowed funds for the listed entity.

8. PAN will not be displayed on the website of the Stock Exchange(s).

9. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.